Literature DB >> 28796925

Neurological comorbidity in children with neurofibromatosis type 1.

Keiko Hirabaru1, Muneaki Matsuo1.   

Abstract

BACKGROUND: The aim of this study was to determine the frequency of central nervous system comorbidities in children with neurofibromatosis type 1 (NF1).
METHODS: We performed a nationwide survey to investigate neurological comorbidities in 3-15-year-old children with NF1 in Japan by sending questionnaires to pediatricians and pediatric neurologists. A secondary questionnaire was sent to the parents of identified NF1 patients to assess neurological comorbidities including headache, attention deficit-hyperactivity disorder (ADHD) Rating Scale (RS), and the Social Responsiveness Scale 2.
RESULTS: The primary survey identified 760 NF1 patients, and the parents of 565 patients were sent the secondary questionnaire. The parental response rate was 25.7% (145; 63 girls, 81 boys, one unspecified). Among the patients, 42.9% (55/128; 35 girls, 20 boys) were reported to exhibit intellectual problems. On the ADHD-RS, 40.2% (47/117) of NF1 patients aged 6-15 had ADHD (RS score >93rd percentile), with a rate of 47.7% in boys and 30.8% in girls. Furthermore, 20.2% of patients had suspected autism spectrum disorder (29/143; 10 girls, 19 boys), with Social Responsiveness Scale score ≥76. Headache was reported by 49.6% (61/123) of children over 5 years old, and 25.2% (31/123; 10 girls, 21 boys) reported migraine. Other neurological comorbidities included 20 cases of epilepsy (13.8%), 11 cases of optic nerve glioma (7.6%), five cases of brain tumor (3.4%), six cases of cerebrovascular disease (4.1%), and two cases of hydrocephalus (1.4%).
CONCLUSION: Intellectual problems, ADHD, autism spectrum disorder, and migraine are major neurological comorbidities in NF1.
© 2017 Japan Pediatric Society.

Entities:  

Keywords:  attention deficit-hyperactivity disorder; autism; comorbidity; migraine; neurofibromatosis type 1

Mesh:

Year:  2017        PMID: 28796925     DOI: 10.1111/ped.13388

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  7 in total

1.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

2.  Epilepsy in NF1: a systematic review of the literature.

Authors:  Pia Bernardo; Giuseppe Cinalli; Claudia Santoro
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

3.  Assessing Psychiatric Comorbidity and Pharmacologic Treatment Patterns Among Patients With Neurofibromatosis Type 1.

Authors:  Alexander C Houpt; Shaina E Schwartz; Robert A Coover
Journal:  Cureus       Date:  2021-12-07

4.  [Clinical aspects of Neurofibromatosis type 1 seen in the Department of Dermatology at University Hospital Antananarivo, Madagascar].

Authors:  Fandresena Arilala Sendrasoa; Aurélie Rasoarisata; Lala Soavina Ramarozatovo; Fahafahantsoa Rapelanoro Rabenja
Journal:  Med Trop Sante Int       Date:  2022-05-27

5.  Epilepsy and Electroencephalogram Characteristics in Children with Neurofibromatosis Type 1, What We Have Learned from a Tertiary Center Five Years' Experience.

Authors:  Abdulhafeez M Khair; Stephen Falchek; Rahul Nikam; Gurcharanjeet Kaur
Journal:  Child Neurol Open       Date:  2022-10-11

6.  Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.

Authors:  Jennifer A Janusz; Bonita P Klein-Tasman; Jonathan M Payne; Pamela L Wolters; Heather L Thompson; Staci Martin; Peter de Blank; Nicole Ullrich; Allison Del Castillo; Maureen Hussey; Kristina K Hardy; Kristina Haebich; Tena Rosser; Mary Anne Toledo-Tamula; Karin S Walsh
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

7.  Epilepsy in NF1: Epidemiologic, Genetic, and Clinical Features. A Monocentric Retrospective Study in a Cohort of 784 Patients.

Authors:  Ugo Sorrentino; Silvia Bellonzi; Chiara Mozzato; Valeria Brasson; Irene Toldo; Raffaele Parrozzani; Maurizio Clementi; Matteo Cassina; Eva Trevisson
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.